As molecular profiling is not performed routinely in all stage III NSCLC undergoing CCRT, there is, therefore, the potential for unidentified EGFR positive or ALK rearranged NSCLC patients to (i) receive limited benefit from the PACIFIC regimen, and (ii) be vulnerable to considerable toxicity if an actionable mutation is found at progression and sequential TKI therapy is employed. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.